COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies
NanoViricides, Inc. proposes Phase II Trial of NV-387 Oral Gummies for Bundibugyo Ebolavirus. Potential treatment for current outbreak, offering oral delivery of broad-spectrum antiviral drug -
-
-
COMMUNIQUÉ DE PRESSE
In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides
NanoViricides, Inc. announces potential treatment option for Ebola Bundibugyo virus strain, highlighting broad-spectrum antiviral drug candidate NV-387, superior to Remdesivir, ready for Phase II clinical trial -
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides Announces Closing of ~$2 Million Registered Direct Offering
NanoViricides, Inc. announces closing of $2M direct offering. Exclusive placement agent D. Boral Capital LLC. SEC registration effective. NV-387, a revolutionary antiviral drug granted Orphan Drug Designation
